Exelixis (EXEL) Treasury Shares (2010 - 2026)
Exelixis (EXEL) posted quarterly Treasury Shares of $18.2 million for Q2 2026, down 19.47% year-over-year from $22.6 million in Q2 2025, and up 5.93% quarter-over-quarter from $17.2 million in Q1 2026.
Exelixis (EXEL) Treasury Shares (2010 - 2026) Analysis & Trends
Exelixis' Treasury Shares history runs 17 years deep, the most recent figure standing at $18.2 million for Q2 2026.
- In Q2 2026, Treasury Shares fell 19.47% year-over-year to $18.2 million; the TTM figure through Apr 2026 stood at $18.2 million (down 19.47% YoY), while the FY2026 annual figure was $17.2 million, up 3726.5% from the prior year.
- Treasury Shares for Q2 2026 stood at $18.2 million, up from $17.2 million in the prior quarter.
- The five-year high for Treasury Shares was $22.6 million in Q2 2025, with the low at $449000.0 in Q1 2025.
- The 5-year median for Treasury Shares is $11.3 million (2023), against an average of $10.2 million.
- The sharpest annual moves came in 2022 and 2025: Treasury Shares surged 6973.54% in 2022, then plunged 96.22% in 2025.
- Exelixis' Treasury Shares stood at $11.3 million in 2022, then climbed by 5.14% to $11.9 million in 2023, then slumped by 93.26% to $800000.0 in 2024, then soared by 2350.0% to $19.6 million in 2025, then retreated by 7.14% to $18.2 million in 2026.
- Business Quant data shows EXEL's Treasury Shares at $18.2 million in Q2 2026, $17.2 million in Q1 2026, and $19.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 16.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 16.40 Mn |
| Jul 3, 2026 | 16.40 Mn |
| Apr 3, 2026 | 18.20 Mn |
| Apr 3, 2026 | 18.20 Mn |
| Jan 2, 2026 | 17.18 Mn |
| Jan 2, 2026 | 17.18 Mn |
| Oct 3, 2025 | 19.60 Mn |
| Oct 3, 2025 | 19.60 Mn |
| Jul 4, 2025 | 20.50 Mn |
| Jul 4, 2025 | 20.50 Mn |
| Apr 4, 2025 | 22.60 Mn |
| Apr 4, 2025 | 22.60 Mn |
| Jan 3, 2025 | 449,000.00 |
| Jan 3, 2025 | 449,000.00 |
| Sep 27, 2024 | 800,000.00 |
| Sep 27, 2024 | 800,000.00 |
| Jun 28, 2024 | 900,000.00 |
| Jun 28, 2024 | 900,000.00 |
| Mar 29, 2024 | 900,000.00 |
| Mar 29, 2024 | 900,000.00 |